Japan Human Diploid Cell Rabies Vaccine Market was valued at USD 0.1 Billion in 2022 and is projected to reach USD 0.15 Billion by 2030, growing at a CAGR of 5.8% from 2024 to 2030.
The Human Diploid Cell Rabies Vaccine (HDCV) market in Japan is experiencing notable growth, driven by increased awareness of rabies prevention and proactive public health initiatives. Forecasts indicate that the Japan rabies vaccine market is projected to reach $78.44 million by 2030, with a compound annual growth rate (CAGR) of 4.3% during the forecast period. citeturn0search0
Japan's low incidence of rabies is attributed to stringent control measures, including mandatory pet vaccinations and wildlife surveillance programs. The country's pet population has been steadily increasing, with over 22 million registered dogs and cats in 2020, reflecting a growing trend of pet ownership among Japanese households. citeturn0search0 This rise in pet ownership underscores the importance of rabies vaccination in protecting both animals and humans.
The market is segmented by prophylaxis type, end user, application, and product type. Notably, the human diploid cell vaccine segment is recognized for its safety and efficacy. A randomized clinical trial demonstrated that HDCV had a better safety profile and higher immunogenicity compared to other vaccines, with 100% positive antibody conversion by day 14 post-vaccination. citeturn0search2
The increasing trend of international travel has heightened the demand for pre-exposure prophylaxis (PrEP) rabies vaccinations. Before the COVID-19 pandemic, Japan was the second-largest contributor of overseas travelers, with an annual influx of 3.8 million visitors, generating $13 billion in spending. citeturn0search0 This robust tourism significantly bolstered the economy, leading to a parallel rise in demand for rabies vaccines among travelers seeking protection against potential exposure.
Several key players contribute to the HDCV market in Japan, including Takeda Pharmaceutical Company Limited, Riken Meijo Co., Ltd., Kaketsuken (the Chemo-Sero-Therapeutic Research Institute), and Kyowa Kirin Co., Ltd. These companies are involved in vaccine development and production, ensuring the availability of safe and effective rabies vaccines. citeturn0search0
In summary, the Human Diploid Cell Rabies Vaccine market in Japan is poised for continued growth, driven by increased pet ownership, international travel, and proactive public health measures. The commitment of pharmaceutical companies to vaccine development and the government's stringent control measures play pivotal roles in maintaining Japan's low incidence of rabies and ensuring public safety.
Get an In-Depth Research Analysis of the Japan Human Diploid Cell Rabies Vaccine Market Size And Forecast [2025-2032]
Â
Sanofi
Wyeth
Chiron Behring
Chengdu Kangh
Shenzhen Biokangtai
Beijing Minhai Biltechnolgy
Â
By the year 2030, the scale for growth in the market research industry is reported to be above 120 billion which further indicates its projected compound annual growth rate (CAGR), of more than 5.8% from 2023 to 2030. There have also been disruptions in the industry due to advancements in machine learning, artificial intelligence and data analytics There is predictive analysis and real time information about consumers which such technologies provide to the companies enabling them to make better and precise decisions. The Asia-Pacific region is expected to be a key driver of growth, accounting for more than 35% of total revenue growth. In addition, new innovative techniques such as mobile surveys, social listening, and online panels, which emphasize speed, precision, and customization, are also transforming this particular sector.
Get Discount On The Purchase of the Japan Human Diploid Cell Rabies Vaccine Market Size And Forecast [2025-2032]
Growing demand for below applications around the world has had a direct impact on the growth of the Japan Human Diploid Cell Rabies Vaccine Market
Pre-Exposure Prophylaxis (PrEP)
Post-Exposure Prophylaxis (PEP)
Combination Vaccines
Dual-Purpose Vaccines (Rabies and other infections)
Animal Bite Prevention
Occupational Vaccination
Travel Vaccination
Research and Development in Veterinary Medicine
Healthcare Providers
Hospitals and Clinics
Pharmacies
Research Institutions
Veterinary Services
Direct Sales
Online Pharmacies
Wholesale Distributors
Retail Pharmacies
Monetary Pricing
Value-Based Pricing
Cost-Plus Pricing
Discounted Pricing for Bulk Orders
Asia-Pacific (China, Japan, Korea, India, Australia, Indonesia, Thailand, Philippines, Malaysia and Vietnam)
For More Information or Query, Visit @ Japan Human Diploid Cell Rabies Vaccine Market Research Analysis
1. Introduction of the Japan Human Diploid Cell Rabies Vaccine Market
Overview of the Market
Scope of Report
Assumptions
2. Executive Summary
3. Research Methodology of Verified Market Reports
Data Mining
Validation
Primary Interviews
List of Data Sources
4. Japan Human Diploid Cell Rabies Vaccine Market Outlook
Overview
Market Dynamics
Drivers
Restraints
Opportunities
Porters Five Force Model
Value Chain Analysis
5. Japan Human Diploid Cell Rabies Vaccine Market, By Type
6. Japan Human Diploid Cell Rabies Vaccine Market, By Application
7. Japan Human Diploid Cell Rabies Vaccine Market, By Geography
Asia-Pacific
China
Japan
Korea
India
Australia
Indonesia
Thailand
Philippines
Malaysia and Vietnam
8. Japan Human Diploid Cell Rabies Vaccine Market Competitive Landscape
Overview
Company Market Ranking
Key Development Strategies
9. Company Profiles
10. Appendix
About Us: Verified Market Reports
Verified Market Reports is a leading Research and Consulting firm servicing over 5000+ clients. We provide advanced analytical research solutions while offering information-enriched research studies. We also offer insights into strategic and growth analyses and data necessary to achieve corporate goals and critical revenue decisions.
Our 250 Analysts and SMEs offer a high level of expertise in data collection and governance using industrial techniques to collect and analyze data on more than 25,000 high-impact and niche markets. Our analysts are trained to combine modern data collection techniques, superior research methodology, expertise, and years of collective experience to produce informative and accurate research.
Contact us:
Mr. Edwyne Fernandes
US: +1 (650)-781-4080
US Toll-Free: +1 (800)-782-1768
Website: https://www.verifiedmarketreports.com/